Late‐onset heart failure after treatment for breast cancer

Ewer, Steven M.; Pham, David

doi:10.1002/cncr.32483

Cited by 4 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pre-existing cardiovascular risk factors and medical comorbidities extracted from the electronic medical records, included: body mass index (BMI), tobacco use, diabetes, hypertension, hyperlipidemia, coronary artery disease, hypothyroidism, and a family history of atherosclerotic cardiovascular disease. Cumulative anthracycline dose was calculated based on the following rapid infusion doxorubicin CTRD equivalence: epirubicin, 0.66; daunorubicin, 0.75; and idarubicin, 0.53 [ 10 , 11 ].…”

Section: Methodsmentioning

confidence: 99%

Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity

Araujo-Gutierrez

Chitturi

et al. 2021

Cardio-Oncology

View full text Add to dashboard Cite

Background Cancer therapy-related cardiac dysfunction (CTRD) is a major source of morbidity and mortality in long-term cancer survivors. Decreased GLS predicts decreased left ventricular ejection fraction (LVEF) in patients receiving anthracyclines, but knowledge regarding the clinical utility of baseline GLS in patients at low-risk of (CTRD) is limited. Objectives The purpose of this study was to investigate whether baseline echocardiographic assessment of global longitudinal strain (GLS) before treatment with anthracyclines is predictive of (CTRD) in a broad cohort of patients with normal baseline LVEF. Methods Study participants comprised 188 patients at a single institution who underwent baseline 2-dimensional (2D) speckle-tracking echocardiography before treatment with anthracyclines and at least one follow-up echocardiogram 3 months after chemotherapy initiation. Patients with a baseline LVEF <55% were excluded from the analysis. The primary endpoint, (CTRD), was defined as an absolute decline in LVEF > 10% from baseline and an overall reduced LVEF <50%. Potential and known risk factors were evaluated using univariable and multivariable Cox proportional hazards regression analysis. Results Twenty-three patients (12.23%) developed (CTRD). Among patients with (CTRD), the mean GLS was -17.51% ± 2.77%. The optimal cutoff point for (CTRD) was -18.05%. The sensitivity was 0.70 and specificity was 0.70. The area under ROC curve was 0.70. After adjustment for cardiovascular and cancer therapy related risk factors, GLS or decreased baseline GLS ≥-18% was predictive of (CTRD) (adjusted hazards ratio 1.17, 95% confidence interval 1.00, 1.36; p = 0.044 for GLS, or hazards ratio 3.54; 95% confidence interval 1.34, 9.35; p = 0.011 for decreased GLS), along with history of tobacco use, pre-chemotherapy systolic blood pressure, and cumulative anthracycline dose. Conclusions Baseline GLS or decreased baseline GLS was predictive of (CTRD) before anthracycline treatment in a cohort of cancer patients with a normal baseline LVEF. This data supports the implementation of strain-protocol echocardiography in cardio-oncology practice for identifying and monitoring patients who are at elevated risk of (CTRD).

show abstract

Section: Methodsmentioning

confidence: 99%

Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity

Araujo-Gutierrez

Chitturi

et al. 2021

Cardio-Oncology

View full text Add to dashboard Cite

show abstract

“…With increased cancer survivorship, there is progressive increase in the incidence of both reversible and irreversible cardiotoxicities mainly due to ionizing radiation, chemotherapy and both targeted and non-targeted immunotherapies. This book, authored by a multidisciplinary team of cardiologists, oncologists, cardiac imagers and research scientists makes a sincere effort to integrate a somewhat fragmented body of scientific literature into a comprehensive textbook [1] .…”

Section: Introductionmentioning

confidence: 99%

Book review: cancer and the heart

Sharma

Pokharel

2021

Cardio-Oncology

View full text Add to dashboard Cite

“…Segundo Patnaik et al 5 , pacientes com câncer de mama acima de 65 anos apresentam maior risco de óbito por doença cardiovascular do que pelo câncer, mesmo se forem diagnosticadas pela neoplasia em estadiamentos iniciais. Os eventos cardíacos após a terapia antineoplásica estão bem documentados na literatura científica [6][7][8] , assim como os óbitos cardiovasculares associados tanto ao diagnóstico como ao tratamento do câncer de mama 9 .…”

Section: Introductionunclassified

Qualidade de Vida Relacionada à Saúde e Risco de Comorbidade Cardiovascular ao Diagnóstico de Câncer de Mama

Aguiar

Rodrigues

Santos

et al. 2019

Rev. Brasileira.De.Cancerologia

View full text Add to dashboard Cite

Introdução: A literatura sugere que mulheres com doenças cardiovasculares apresentam pior qualidade de vida ao diagnóstico de câncer de mama. Objetivo: Avaliar a associação entre a qualidade de vida relacionada à saúde (QVRS) e as doenças cardiovasculares ao diagnóstico de câncer de mama. Método: Estudo transversal com mulheres diagnosticadas com câncer de mama. A QVRS foi avaliada pelos questionários European Organization for Research and Treatment of Cancer Quality of Life Questionnarie (EORTC QLQ-C30) and Breast Câncer Module (QLQ-BR23) e a comorbidade por meio da Cumulative Illness Rating Scale Geriatric (CIRS-G). Foram calculadas as diferenças entre as médias dos escores de QVRS e comorbidade. A associação foi avaliada por regressão logística múltipla. Resultados: Foram incluídas 953 mulheres com média de idade de 54 anos (DP±11,7). Apresentavam alguma comorbidade ao diagnóstico de câncer de mama 84,1% das mulheres. O sistema coração foi afetado em 10,8% e o sistema vascular em 48,2%. Após ajuste, observou-se associação entre os escores das funções física e sexual e problemas nos sistemas coração e vascular. Foi ainda observada associação entre os piores escores de dor e dispneia e o sistema coração. Em relação à presença de doenças no sistema vascular, este esteve associado à melhor satisfação sexual, melhor perspectiva futura e piores sintomas na mama. Conclusão: A QVRS se mostrou associada a doenças cardiovasculares em pacientes com câncer de mama em relação à função física, sexual, satisfação sexual, perspectivas futuras e as escalas de sintomas (dor, dispneia e sintomas na mama).

show abstract

Late‐onset heart failure after treatment for breast cancer

Abstract: Late‐onset heart failure after breast cancer is a rare event. It is necessary to remain vigilant for cardiac complications after potentially toxic cancer treatments.

Cited by 4 publications

References 7 publications

Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity

Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity

Book review: cancer and the heart

Qualidade de Vida Relacionada à Saúde e Risco de Comorbidade Cardiovascular ao Diagnóstico de Câncer de Mama

Contact Info

Product

Resources

About